JP2013520514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520514A5 JP2013520514A5 JP2012555111A JP2012555111A JP2013520514A5 JP 2013520514 A5 JP2013520514 A5 JP 2013520514A5 JP 2012555111 A JP2012555111 A JP 2012555111A JP 2012555111 A JP2012555111 A JP 2012555111A JP 2013520514 A5 JP2013520514 A5 JP 2013520514A5
- Authority
- JP
- Japan
- Prior art keywords
- abuse
- patent document
- patients
- drug
- international
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000025940 Back injury Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30758810P | 2010-02-24 | 2010-02-24 | |
| US61/307,588 | 2010-02-24 | ||
| PCT/US2011/025914 WO2011106416A2 (en) | 2010-02-24 | 2011-02-23 | Abuse-resistant formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520514A JP2013520514A (ja) | 2013-06-06 |
| JP2013520514A5 true JP2013520514A5 (cg-RX-API-DMAC10.html) | 2014-04-10 |
| JP6141583B2 JP6141583B2 (ja) | 2017-06-07 |
Family
ID=43896837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555111A Expired - Fee Related JP6141583B2 (ja) | 2010-02-24 | 2011-02-23 | 濫用耐性製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130209560A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2538928B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6141583B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN102770127B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2011220813B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2790108C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2628886T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL221409A (cg-RX-API-DMAC10.html) |
| MX (1) | MX347753B (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ602075A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011106416A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| WO2009114648A1 (en) | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| PL2826467T3 (pl) | 2010-12-22 | 2018-01-31 | Purdue Pharma Lp | Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| HRP20170864T1 (hr) * | 2011-06-01 | 2017-08-25 | Fmc Corporation | Čvrsti dozni oblici s kontroliranim oslobađanjem |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| RU2665372C2 (ru) * | 2012-09-03 | 2018-08-29 | Дайити Санкио Компани, Лимитед | Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона |
| PL3164117T3 (pl) | 2014-07-03 | 2024-03-11 | SpecGx LLC | Preparaty zapewniające natychmiastowe uwalnianie i powstrzymujące przed nadużywaniem, zawierające polisacharydy inne niż celuloza |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| WO2018013771A1 (en) * | 2016-07-13 | 2018-01-18 | Cima Labs Inc. | Treatment of pain using hydrocodone formulations |
| WO2018119033A1 (en) * | 2016-12-20 | 2018-06-28 | Cima Labs Inc. | Abuse-resistant and abuse-deterrent dosage forms |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
| IT201800011125A1 (it) | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| IT202000011053A1 (it) | 2020-05-14 | 2021-11-14 | Int Health Science S R L | Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di alimenti, integratori alimentari, nutraceutici, dispositivi medici |
| IT202000011050A1 (it) | 2020-05-14 | 2021-11-14 | Mogon Pharmaceuticals Sagl | Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959219A (en) * | 1988-08-15 | 1990-09-25 | Fisons Corporation | Coating barriers comprising ethyl cellulose |
| US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| EP2295043A1 (en) * | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| DE10025947A1 (de) * | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit |
| DE10025948A1 (de) * | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination |
| ATE345112T1 (de) * | 2001-05-11 | 2006-12-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
| US6813297B2 (en) * | 2002-07-16 | 2004-11-02 | Agilent Technologies, Inc. | Material systems for long wavelength lasers grown on GaSb or InAs substrates |
| SI1551372T1 (en) * | 2002-09-20 | 2018-08-31 | Alpharma Pharmaceuticals Llc | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES |
| FR2881652B1 (fr) * | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
| US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
| FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| HUE032012T2 (en) * | 2007-09-13 | 2017-08-28 | Cima Labs Inc | Anti-Abuse Drug Products |
| EP2219612A4 (en) * | 2007-12-17 | 2013-10-30 | Paladin Labs Inc | FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION |
-
2011
- 2011-02-23 ES ES11705797.6T patent/ES2628886T3/es active Active
- 2011-02-23 JP JP2012555111A patent/JP6141583B2/ja not_active Expired - Fee Related
- 2011-02-23 CA CA2790108A patent/CA2790108C/en not_active Expired - Fee Related
- 2011-02-23 NZ NZ602075A patent/NZ602075A/en unknown
- 2011-02-23 CN CN201180011055.7A patent/CN102770127B/zh not_active Expired - Fee Related
- 2011-02-23 WO PCT/US2011/025914 patent/WO2011106416A2/en not_active Ceased
- 2011-02-23 MX MX2012009780A patent/MX347753B/es active IP Right Grant
- 2011-02-23 EP EP11705797.6A patent/EP2538928B1/en active Active
- 2011-02-23 US US13/719,908 patent/US20130209560A1/en not_active Abandoned
- 2011-02-23 AU AU2011220813A patent/AU2011220813B2/en not_active Ceased
-
2012
- 2012-08-12 IL IL221409A patent/IL221409A/en not_active IP Right Cessation
-
2017
- 2017-11-02 US US15/802,276 patent/US20180049974A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vu et al. | Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer | |
| UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
| EP2629828A4 (en) | DEVICE FOR TURNING MEDICAL DEVICES, SYSTEMS WITH THIS DEVICE AND RELATED METHOD | |
| EA200901263A1 (ru) | Конденсированный аминопиридин в качестве ингибиторов hsp90 | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| BR112014032917A2 (pt) | compostos e usos terapêuticos dos mesmos | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| IL227623B (en) | Nanoparticle compositions comprising a population of particles, for use in the manufacture of a topical medicament for treating a subject suffering from or susceptible to a condition or disorder associated with sweat glands and/or sebaceous glands | |
| EP2142244A4 (en) | MEDICAL DEVICE FOR DISPOSING A MEDICAMENT AND / OR FOR IMPLEMENTING PHYSICAL THERAPY | |
| MX382604B (es) | Un inmunosupresor para usarse en la inducción de tolerancia a una molécula terapéutica. | |
| MX2014010913A (es) | Composicion farmaceutica que comprende farmaco empagliflozina y antiobesidad. | |
| MX2015017961A (es) | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. | |
| EP2802319A4 (en) | FESTDOSIS COMBINATION THERAPY OF MORBUS PARKINSON | |
| Long et al. | Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma | |
| Torban et al. | Practices and attitudes of addiction treatment providers in the Russian Federation | |
| EA200900923A1 (ru) | Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний | |
| Irving et al. | 15 minute consultations as standard benefit patients and GPs | |
| Mehran et al. | Prayer and physical pains | |
| Mösges et al. | Nonpharmacological treatment of rhinoconjunctivitis and rhinosinusitis | |
| Mohammadi et al. | Medicinal herbs are effective in the treatment of kidney and urinary tract diseases from the viewpoints Islamic medicine | |
| Chauhan et al. | Looking in the past for the future | |
| Sullivan | NAME _ | |
| Gupta et al. | Evaluation And Compare The Efficacy Of Kaishora Guggulu Plus Amrita Guggulu In The Management Of Utthana Vatarakta Wsr To Gout | |
| Smith et al. | THE EFFECTIVENESS OF OSTEOPATHIC MANIPULATIVE TREATMENT FOR MECHANICAL LOW BACK PAIN | |
| Chavant | Carpal canal syndrome worsening: case report |